R
Robert M. Langdon
Researcher at Houston Methodist Hospital
Publications - 17
Citations - 2161
Robert M. Langdon is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Pembrolizumab & Health care. The author has an hindex of 11, co-authored 16 publications receiving 1792 citations.
Papers
More filters
Journal ArticleDOI
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper,Nancy E. Davidson,Dana S. Wollins,Courtney Tyne,Douglas W. Blayney,Diane Blum,Adam P. Dicker,Patricia A. Ganz,J. Russell Hoverman,Robert M. Langdon,Gary H. Lyman,Neal J. Meropol,Therese M. Mulvey,Lee N. Newcomer,Jeffrey Peppercorn,Blase N. Polite,Derek Raghavan,Gregory Rossi,Leonard B. Saltz,Deborah Schrag,Thomas J. Smith,Peter Paul Yu,Clifford A. Hudis,Richard L. Schilsky +23 more
TL;DR: The high costs associated with cancer care have created a difficult situation for patients and the oncologists who care for them and will require greater understanding of all the risks and benefits of various treatment options as well as the consequences of specific choices.
Journal ArticleDOI
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Neal J. Meropol,Deborah Schrag,Thomas J. Smith,Therese M. Mulvey,Robert M. Langdon,Diane Blum,Peter A. Ubel,Lowell E. Schnipper +7 more
TL;DR: A clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system, are required to ensure that all Americans have access to high-quality, cost-effective care.
Journal ArticleDOI
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper,Nancy E. Davidson,Dana S. Wollins,Douglas W. Blayney,Adam P. Dicker,Patricia A. Ganz,J. Russell Hoverman,Robert M. Langdon,Gary H. Lyman,Neal J. Meropol,Therese M. Mulvey,Lee N. Newcomer,Jeffrey Peppercorn,Blase N. Polite,Derek Raghavan,Gregory Rossi,Leonard B. Saltz,Deborah Schrag,Thomas J. Smith,Peter Paul Yu,Clifford A. Hudis,Julie M. Vose,Richard L. Schilsky +22 more
TL;DR: The value framework has been constructed as a conceptual model that incorporates the elements of clinical benefit, toxicity, and symptom palliation as derived from a comparative clinical trial and combines these elements into a score termed the net health benefit (NHB).
Journal ArticleDOI
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier cancer research network LUN 14‐179
Greg Andrew Durm,Salma K. Jabbour,Sandra Althouse,Ziyue Liu,Ahad Ali Sadiq,Robin Zon,Shadia I. Jalal,Shadia I. Jalal,Goetz H. Kloecker,Michael J. Williamson,Karen L. Reckamp,Robert M. Langdon,Ebenezer A. Kio,Ryan D. Gentzler,Bamidele A. Adesunloye,Wael A. Harb,Radhika V. Walling,Michael L. Titzer,Nasser H. Hanna +18 more
TL;DR: This trial evaluated pembrolizumab as consolidation therapy after concurrent chemoradiation in patients with unresectable stage III disease and demonstrated improved OS.
Journal ArticleDOI
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M. Evens,Sriram Balasubramanian,Julie M. Vose,Wael A. Harb,Leo I. Gordon,Robert M. Langdon,Julian Sprague,Mint Sirisawad,Chitra Mani,Jeanne Yue,Ying Luan,Sharon Horton,Thorsten Graef,Nancy L. Bartlett +13 more
TL;DR: The pan-HDACi, abexinostat, was overall well tolerated and had significant clinical activity in follicular lymphoma, including highly durable responses in this multiply relapsed patient population.